![Insights from 2024 EHA Annual Meeting](http://media.vumedi.com/thumbs/channel_logo/2024/6/8d846ca9-a80f-4328-885e-a4302b90cd59.png.200x0_q85.png)
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: Final 5-Year Results of Olutasidenib for Mutated IDH1 AML
By
Insights from 2024 EHA Annual Meeting
FEATURING
Jorge Cortés
By
Insights from 2024 EHA Annual Meeting
FEATURING
Jorge Cortés
Login to view comments.
Click here to Login